-
ACCELERATING RWE TREATMENT PATTERN SYNTHESIS THROUGH AI-ASSISTED LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF PROVIDING FULL HOME ENTERAL NUTRITION THROUGH THE PUBLIC HEALTH SYSTEM IN SãO PAULO, BRAZIL
Aug 11, 2026, 17:16 PM -
AMPLIFIED GLOBAL WELFARE EFFECTS OF NICE'S PROPOSED 25% COST-EFFECTIVENESS THRESHOLD UPLIFT THROUGH INTERNATIONAL REFERENCE PRICING
Aug 11, 2026, 17:16 PM -
LIVING POST-MARKETING SURVEILLANCE OF SAFETY, TREATMENT PERSISTENCE AND SAFETY OUTCOMES FOR ZANUBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A REAL-TIME AI-ASSISTED SYSTEMATIC LITERATURE REVIEW (REAL-SLR)
Aug 11, 2026, 17:16 PM -
AN LLM AGENT BUILDS A FUNCTIONAL COST-EFFECTIVENESS MODEL IN EXCEL WITH LIVE FORMULAS AND VBA MACROS FROM A WRITTEN SPECIFICATION: A NOVEL ARCHITECTURAL APPROACH
Aug 11, 2026, 17:16 PM -
COUNTING WHAT COUNTS; THE VISIBILITY OF HEALTH POLICY AND EQUITY IN HEALTH ECONOMICS RESEARCH: AN EMPIRICAL REVIEW
Aug 11, 2026, 17:16 PM -
ELECTROACUPUNCTURE AS A NON-PHARMACOLOGIC ADJUNCT FOR POSTOPERATIVE RECOVERY FOLLOWING TOTAL KNEE ARTHROPLASTY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Aug 11, 2026, 17:16 PM -
A LARGE POPULATION WITH CLINICALLY MEANINGFUL EVIDENCE OF ALCOHOL USE DISORDER (AUD) IS NOT CAPTURED BY DIAGNOSIS CODES ALONE: EVIDENCE FROM NORSTELLALINQ STRUCTURED AND HUMAN-IN-THE-LOOP LARGE LANGUAGE MODEL (LLM) EXTRACTED CLINICAL DATA
Aug 11, 2026, 17:16 PM -
INCIDENCE PATTERNS OF POST-COVID SYNDROME IN GERMANY BETWEEN 2021 AND 2024: EVIDENCE FROM STATUTORY HEALTH INSURANCE CLAIMS DATA
Aug 11, 2026, 17:16 PM -
BURDEN OF THALASSEMIA IN SAUDI ARABIA: REAL-WORLD EVIDENCE FROM THE NATIONAL UNIFIED ELECTRONIC HEALTH RECORD SYSTEM
Aug 11, 2026, 17:16 PM -
VALUE CONTRIBUTION OF DONIDALORSEN FOR THE LONG-TERM PROPHYLAXIS OF HEREDITARY ANGIOEDEMA IN SPAIN: A MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Aug 11, 2026, 17:16 PM -
MEASURING USER ATTITUDES AND PREFERENCES TOWARDS THE USE OF AI-ENABLED HEALTH TECHNOLOGIES: A SCOPING REVIEW PROTOCOL
Aug 11, 2026, 17:16 PM -
THE LONG-TERM COST-EFFECTIVENESS OF SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE IN THE UAE
Aug 11, 2026, 17:16 PM -
RISING DRUG COSTS WITH STABLE 12-MONTH SURVIVAL IN INCIDENT METASTATIC BREAST CANCER IN GERMANY, 2011-2024
Aug 11, 2026, 17:16 PM -
CUMULATIVE ECONOMIC AND SOCIETAL BURDEN OF GRADE 2 MIDH GLIOMA ON PATIENTS AND CAREGIVERS, STRATIFIED BY RADIOTHERAPY/CHEMOTHERAPY EXPOSURE
Aug 11, 2026, 17:16 PM -
REAL-WORLD OBESITY AND GLP-1RA TOLERABILITY: INCIDENCE AND PROGNOSTIC RISK FACTORS OF SERIOUS GI ADVERSE EVENTS USING FEDERATED LEARNING
Aug 11, 2026, 17:16 PM -
NICE COMMITTEE DECISIONS AND REASONING AROUND ACCEPTABLE ICERS IN THE YEAR LEADING UP TO THE APRIL 2026 THRESHOLD RANGE CHANGE
Aug 11, 2026, 17:16 PM -
HOW DO HTA SYSTEMS AND PAYERS RECOGNISE THERAPEUTIC COMPARABILITY? A CROSS-MARKET ASSESSMENT OF COST-ADVANTAGE REIMBURSEMENT PATHWAYS
Aug 11, 2026, 17:16 PM -
DEVELOPMENT AND STRUCTURAL BENCHMARKING OF THE ASSURE-SSP MODEL: ASUNDEXIAN REFERENCE ECONOMIC MODEL IN SECONDARY STROKE PREVENTION
Aug 11, 2026, 17:16 PM -
DUAL BRAND STRATEGY IN GERMAN DRUG PRICING: LIMITED OPPORTUNITY BASED ON AMNOG FRAMEWORK WITH EXCEPTIONS?
Aug 11, 2026, 17:16 PM
